X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with Piramal Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs PIRAMAL ENTERPRISES - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA PIRAMAL ENTERPRISES SUN PHARMA/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 15.5 37.0 42.0% View Chart
P/BV x 3.7 3.7 99.1% View Chart
Dividend Yield % 0.2 0.7 31.8%  

Financials

 SUN PHARMA   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    SUN PHARMA
Mar-16
PIRAMAL ENTERPRISES
Mar-16
SUN PHARMA/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs1,2011,065 112.7%   
Low Rs706805 87.8%   
Sales per share (Unadj.) Rs117.5383.0 30.7%  
Earnings per share (Unadj.) Rs19.655.1 35.6%  
Cash flow per share (Unadj.) Rs23.874.1 32.1%  
Dividends per share (Unadj.) Rs1.0017.50 5.7%  
Dividend yield (eoy) %0.11.9 5.6%  
Book value per share (Unadj.) Rs130.5719.9 18.1%  
Shares outstanding (eoy) m2,406.60172.56 1,394.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x8.12.4 332.6%   
Avg P/E ratio x48.717.0 286.7%  
P/CF ratio (eoy) x40.112.6 317.3%  
Price / Book Value ratio x7.31.3 562.6%  
Dividend payout %5.131.8 16.1%   
Avg Mkt Cap Rs m2,294,813161,344 1,422.3%   
No. of employees `00014.73.8 389.8%   
Total wages/salary Rs m47,97116,898 283.9%   
Avg. sales/employee Rs Th19,169.817,472.6 109.7%   
Avg. wages/employee Rs Th3,253.04,466.9 72.8%   
Avg. net profit/employee Rs Th3,197.92,512.8 127.3%   
INCOME DATA
Net Sales Rs m282,69766,099 427.7%  
Other income Rs m6,1702,425 254.5%   
Total revenues Rs m288,86768,524 421.6%   
Gross profit Rs m83,23918,723 444.6%  
Depreciation Rs m10,1353,274 309.5%   
Interest Rs m4,7699,388 50.8%   
Profit before tax Rs m74,5058,485 878.1%   
Minority Interest Rs m-11,1263 -337,151.5%   
Prior Period Items Rs m-191,593 -1.2%   
Extraordinary Inc (Exp) Rs m-6,852457 -1,500.3%   
Tax Rs m9,3491,032 906.0%   
Profit after tax Rs m47,1599,506 496.1%  
Gross profit margin %29.428.3 104.0%  
Effective tax rate %12.512.2 103.2%   
Net profit margin %16.714.4 116.0%  
BALANCE SHEET DATA
Current assets Rs m308,64647,488 649.9%   
Current liabilities Rs m132,477104,362 126.9%   
Net working cap to sales %62.3-86.0 -72.4%  
Current ratio x2.30.5 512.0%  
Inventory Days Days8341 204.2%  
Debtors Days Days8851 171.6%  
Net fixed assets Rs m133,60626,532 503.6%   
Share capital Rs m2,407345 697.4%   
"Free" reserves Rs m266,909114,024 234.1%   
Net worth Rs m314,042124,221 252.8%   
Long term debt Rs m31,16775,812 41.1%   
Total assets Rs m542,196308,356 175.8%  
Interest coverage x16.61.9 873.1%   
Debt to equity ratio x0.10.6 16.3%  
Sales to assets ratio x0.50.2 243.2%   
Return on assets %9.66.1 156.3%  
Return on equity %15.07.7 196.2%  
Return on capital %17.810.0 178.2%  
Exports to sales %14.017.2 81.4%   
Imports to sales %3.16.6 47.6%   
Exports (fob) Rs m39,57211,362 348.3%   
Imports (cif) Rs m8,8824,364 203.5%   
Fx inflow Rs m42,17114,435 292.1%   
Fx outflow Rs m21,5835,183 416.5%   
Net fx Rs m20,5889,253 222.5%   
CASH FLOW
From Operations Rs m67,694-67,773 -99.9%  
From Investments Rs m-44,549-8,768 508.1%  
From Financial Activity Rs m-19,24376,199 -25.3%  
Net Cashflow Rs m3,902-342 -1,139.5%  

Share Holding

Indian Promoters % 63.7 52.9 120.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 4.0 128.3%  
FIIs % 23.0 26.6 86.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 16.5 50.3%  
Shareholders   133,026 93,274 142.6%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   PLETHICO PHARMA  BIOCON LTD  J.B.CHEMICALS  ALKEM LABORATORIES  AJANTA PHARMA  

Compare SUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens in Green; Tata Stocks in Focus(09:30 am)

Asian stock indices are lower today as Japanese and Hong Kong shares fall. The Nikkei 225 is off 0.13% while the Hang Seng is down 0.54%. The Shanghai Composite is trading down by 0.02%.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

Dear PM Modi, India is Already Land of Self-Employed, and It Ain't Working(Vivek Kaul's Diary)

Aug 21, 2017

Most Indians who cannot find jobs, look at becoming self-employed.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

Think Twice Before You Keep Money In A Savings Bank Account(Outside View)

Aug 22, 2017

Post demonetisation, a cut in bank savings deposits rates was in the offing.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Aug 24, 2017 11:03 AM

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA 8-QTR ANALYSIS

COMPARE SUN PHARMA WITH

MARKET STATS